While last month saw many pharma executives leaving their positions to head towards smaller biotech companies, this month saw members of the industry climbing the ladder from various different starting points.
The bulk of biotech companies are firmly rooted towards the foot of
the ladder of corporate evolution. Precious few can realistically
claim to be at the top end of the evolutionary scale with full
R&D capabilities, global reach...